By Business Wire
Publication Date: 2026-04-15 21:25:00
The new service offering combines GNQ Insilico’s Causal AI Drug Assessment, Drug Simulation and Digital Twin platforms with IBM’s consulting and hybrid cloud expertise.
SAN JOSE, Calif., April 15, 2026– (BUSINESS WIRE) – GNQ Insilico, Inc. (GNQ), a TechBio precision medicine company, today announced a collaboration with IBM aimed at helping healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine. Through this collaboration, GNQ will provide its causal AI drug evaluation, drug simulation and digital twin platforms, supported by IBM’s consulting expertise and experience in hybrid cloud deployment. The collaboration will be formalized through a global joint initiative marketing agreement signed in March 2026.
Failure rates in clinical trials remain high and treatment decisions are often made without comprehensive insight into the biology of the individual patient. The platforms are designed to address these challenges by combining GNQs…
